37.40
3.03%
+1.10
전일 마감가:
$36.30
열려 있는:
$37.35
하루 거래량:
527.28K
시가총액:
$2.29B
수익:
$78.59M
순이익/손실:
$-146.96M
주가수익비율:
-13.55
EPS:
-2.76
순현금흐름:
$-137.31M
1주 성능:
+12.08%
1개월 성능:
+0.73%
6개월 성능:
+162.09%
1년 성능:
+21.04%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5300
주소
200 Arsenal Yards Boulevard, Suite 230, Watertown
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-02-15 | 개시 | Wolfe Research | Peer Perform |
2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2023-06-30 | 개시 | Truist | Buy |
2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2022-11-08 | 개시 | Raymond James | Mkt Perform |
2022-08-15 | 개시 | Jefferies | Buy |
2022-08-03 | 개시 | Goldman | Buy |
2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
2022-04-28 | 개시 | Credit Suisse | Outperform |
2022-03-10 | 개시 | JP Morgan | Neutral |
2022-02-10 | 개시 | Wells Fargo | Overweight |
2021-09-30 | 개시 | B. Riley Securities | Neutral |
2021-09-30 | 개시 | Stifel | Buy |
2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
2021-05-21 | 개시 | UBS | Buy |
2021-04-14 | 개시 | Berenberg | Buy |
2020-12-04 | 개시 | H.C. Wainwright | Buy |
2020-09-15 | 개시 | BofA Securities | Neutral |
2020-09-15 | 개시 | Cowen | Outperform |
2020-09-15 | 개시 | Guggenheim | Buy |
2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks Investment Research
Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know
Zacks Investment Research
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire Inc.
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Zacks Investment Research
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Benzinga
Kymera Therapeutics Inc (KYMR) 재무 분석
Kymera Therapeutics Inc (KYMR) 매출 2024
KYMR은 2023-12-31 종료 분기에 대해 매출(지난 12개월)이 78.59M 달러로 보고했으며, 전년대비 +67.84% 상승했습니다.
Kymera Therapeutics Inc (KYMR) 순이익 2024
KYMR은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -146.96M 달러로 보고했으며, 전년대비 +5.07% 증가했습니다.
Kymera Therapeutics Inc (KYMR) 현금흐름 2024
2023-12-31 종료 분기에 KYMR은 현금흐름(지난 12개월)으로 -137.31M 달러를 기록했으며, 전년 대비 +11.94% 증가했습니다.
Kymera Therapeutics Inc (KYMR) 주당 순이익 2024
KYMR이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -2.52달러이며, 전년 대비 +12.50% 성장했습니다.
Kymera Therapeutics Inc 주식 (KYMR) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Booth Bruce | Director |
Mar 14 '24 |
Sale |
39.98 |
55,779 |
2,229,927 |
819,151 |
Booth Bruce | Director |
Mar 13 '24 |
Sale |
42.23 |
139,255 |
5,880,415 |
828,830 |
Atlas Venture Fund X, L.P. | 10% Owner |
Mar 13 '24 |
Sale |
42.23 |
115,090 |
4,859,993 |
4,676,075 |
Atlas Venture Fund X, L.P. | 10% Owner |
Mar 13 '24 |
Sale |
42.23 |
24,165 |
1,020,422 |
828,830 |
Booth Bruce | Director |
Mar 12 '24 |
Sale |
41.98 |
162,918 |
6,838,813 |
852,995 |
Atlas Venture Fund X, L.P. | 10% Owner |
Mar 12 '24 |
Sale |
41.98 |
134,647 |
5,652,072 |
4,791,165 |
Atlas Venture Fund X, L.P. | 10% Owner |
Mar 12 '24 |
Sale |
41.98 |
28,271 |
1,186,741 |
852,995 |
Booth Bruce | Director |
Mar 11 '24 |
Sale |
42.85 |
51,184 |
2,193,148 |
881,266 |
Atlas Venture Fund X, L.P. | 10% Owner |
Mar 11 '24 |
Sale |
42.85 |
42,302 |
1,812,586 |
4,925,812 |
Atlas Venture Fund X, L.P. | 10% Owner |
Mar 11 '24 |
Sale |
42.85 |
8,882 |
380,562 |
881,266 |
자본화:
|
볼륨(24시간):